Dr. Dipenkumar K. Modi, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 134
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MI license 4301101133
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Harper University Hospital Detroit, MI
- Karmanos Cancer Center Detroit, MI
Medical groups
- Barbara Ann Karmanos Cancer Institute (57 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 134
- Services billed
- 734
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 160 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 129 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 127 | 54 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Detroit, MI | 56 |
| Ondansetron Hcl Other prescribers in Detroit, MI | 18 |
| Prednisone Other prescribers in Detroit, MI | 18 |
| Calquence (acalabrutinib maleate) | 17 |
| Allopurinol Other prescribers in Detroit, MI | 17 |
| Prochlorperazine Maleate Other prescribers in Detroit, MI | 17 |
| Pantoprazole Sodium Other prescribers in Detroit, MI | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $18,183 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $13,905 |
|---|---|
| Incyte Corporation | $2,055 |
| E.r. Squibb & Sons, L.l.c. | $1,910 |
| Genentech USA, Inc. | $146 |
| Beigene USA, Inc. | $144 |
| Beone Medicines USA, Inc. | $23.00 |
| Consulting Fee | $17,870 |
|---|---|
| Food and Beverage | $313 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $7,416 |
| Incyte Corporation Jun 12, 2025 | Consulting Fee | $2,055 |
| E.r. Squibb & Sons, L.l.c. Sep 24, 2025 | Consulting Fee | $1,910 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $1,854 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $1,854 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $927 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $927 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee | $927 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 12 companies. The companies reported $1,389,766 in research payments for these studies, mostly to the institutions running them.
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091254 - A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Celgene Corporation · Active, not recruiting · NCT04245839 - Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2
Genentech, Inc. - A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.
Genmab U.S., Inc. - A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant…
National Marrow Donor Program - A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Beone Medicines USA, Inc. · Recruiting · NCT05006716 - Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
AbbVie Inc. · Completed · NCT03112174 - A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
National Marrow Donor Program - Polarix
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.